St. Jude appoints Mark Carlson as CMO
This article was originally published in The Gray Sheet
Effective Nov. 13, Mark Carlson, MD, becomes chief medical officer and senior VP-clinical affairs for St. Jude Medical's cardiac rhythm management division. Carlson recently chaired the Heart Rhythm Society's task force to develop recommendations for post-market surveillance of implantable heart devices, issued Sept. 28 (1"The Gray Sheet" Oct. 2, 2006, p. 3). Carlson will coordinate clinical studies on new and existing heart devices and therapies and will serve as a liaison to the medical community...
You may also be interested in...
The Heart Rhythm Society's final recommendations for industry, FDA and physicians on handling malfunctions of implantable heart devices, issued Sept. 28, "are only the beginning of what needs to happen," said HRS President Dwight Reynolds, MD
Public Company Edition: Lixte’s small uplisting was the only biopharma initial public offering in the US during Thanksgiving week, but IPOs are ramping up again. Also, LifeSci launched its second SPAC and in follow-on offerings Reata brought in $281m and Intellia grossed $175m.
Orladeyo is the first oral prophylactic approved in the US for hereditary angioedema, with Japan and EU approvals expected to follow. Pricing of $485,000 a year undercuts segment leader.